Chemomab Therapeutics Ltd. (CMMB) SEC Filings & Earnings Calls
EquiReason read 16 Chemomab Therapeutics Ltd. SEC filings in the last 12 months. Latest: 6-K on 2026-10-19 — Amendment to merger agreement for redomiciliation and merger with Scipher Medicine; reduces combined company shares to 5M; CVR agreement amended..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 7.5M
- P/E TTM
- 1.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
19 Oct 20266-KAmendment to merger agreement for redomiciliation and merger with Scipher Medicine; reduces combined company shares to 5M; CVR agreement amended.open
Figures in the filing · each found in the filing text
| Combined company outstanding shares · post-merger | 5,000,000 | -50% y/y |
Risks flagged
Merger and redomiciliation involve execution risk, shareholder approval, and regulatory approvals.
“Risks include failure to obtain shareholder approval, regulatory approvals, and uncertainties about timing.”
CVR milestones may not be achieved, leading to no contingent payments.
“CVRs are contingent on milestones; no guarantee of payment.”
30 Sep 20266-KChemomab Therapeutics amends merger agreement with Scipher Medicine; redomiciling to US and reverse merger; combined company to have 10M shares outstanding, ticker SCIP.open
Figures in the filing · each found in the filing text
| combined company shares outstanding · Q4-2026 | 10,000,000 |
Risks flagged
Transaction risk: shareholder approval required; market conditions may affect closing.
“risk that the conditions to the closing of the Domestication Merger or the Merger are not satisfied” · word for word
19 Aug 20266-KChemomab Therapeutics filed unaudited Q2 2026 financial results via Form 6-K; no revenue, net loss, cash burn continues; pre-revenue biotech with merger agreement announced in July 2026.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $6M | |
| Short term bank deposits · Q2-2026 | $688000.00 | |
| Total current assets · Q2-2026 | $10M | |
| Total assets · Q2-2026 | $10M | |
| Total current liabilities · Q2-2026 | $2M | |
| Accumulated deficit · Q2-2026 | $116M |
Risks flagged
Cash burn without revenue; limited liquidity runway.
“Cash and equivalents $5.999M, down from $7.564M; no revenue disclosed.”
Merger agreement may fail or dilute shareholders.
“Subsequent event merger agreement dated July 7, 2026; terms not disclosed.”
16 Jul 2026SC 13DHBM Healthcare Investments files Schedule 13D disclosing 12.5% beneficial ownership and enters into a shareholder support agreement for a merger with Scipher Medicine.open
Figures in the filing · each found in the filing text
| Beneficial Ownership Percentage · 2026-07-16 | 12.5% |
Risks flagged
Merger Completion Risk
“The Merger is expected to be completed in the fourth calendar quarter of 2026, and if it is completed...” · word for word
16 Jul 2026SC 13DHBM Healthcare Investments files Schedule 13D disclosing 12.5% beneficial ownership and enters into a shareholder support agreement for a merger with Scipher Medicine.open
Figures in the filing · each found in the filing text
| Beneficial Ownership Percentage · 2026-07-16 | 12.5% |
Risks flagged
Merger Completion Risk
“The Merger is expected to be completed in the fourth calendar quarter of 2026, and if it is completed...” · word for word
8 Jul 20266-KChemomab Therapeutics enters into merger agreement with Scipher Medicine, becoming a wholly owned subsidiary; combined company to be named Scipher Medicine, listed as SCIP. Concurrent PIPE of at least $30M. CVRs for legacy asset milestones.being acquiredopen
Risks flagged
Execution risk of merger and domestication; CVR milestone dependency; shareholder dilution; tax ruling conditions
“Merger subject to closing conditions, tax rulings from Israel Tax Authority; CVRs contingent on nebokitug milestones”
2 Jun 20266-KChemomab Therapeutics appointed Gwen Melincoff to the Board and made committee changes following resignations of two directors.open
Risks flagged
Resignations of two directors, though stated not due to disagreements.
“Mr. Claude Nicaise and Ms. Jill Quigley resigned from the Board.”
14 May 20266-KChemomab reported new clinical and translational data for nebokitug in PSC, including AI-driven proteomic analysis and gene expression program data; advancing partnering discussions.open
Risks flagged
Clinical and regulatory risk: nebokitug is still in Phase 2; FDA approval not guaranteed; partnering discussions may not materialize.
“Company Continues to Advance Multiple Partnering Options for Nebokitug... We believe that nebokitug could become the first FDA-approved disease-modifying treatment for PSC” · word for word
23 Mar 202620-FAnnual report (20-F) detailing clinical progress for nebokitug in PSC, FDA alignment on Phase 3, and ongoing risks.open
Risks flagged
Geopolitical risk from Israel operations
“Our research and development facilities and certain of our executives are located in Israel and certain of our product candidates may be manufactured at third-party facilities located in Europe.” · word for word
Dependence on additional capital
“If we need to increase our expenditures to fund commercialization activities for nebokitug, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all.” · word for word
Commercialization risk without sales infrastructure
“We do not have any infrastructure for the sales, marketing or distribution of nebokitug, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so.” · word for word
21 Nov 20256-KChemomab reported Q3 2025 net loss of $1.7M, cash $10.2M; Phase 3 design near completion; cash runway through Q4 2026.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and short-term bank deposits · Q3-2025 | $10M | |
| Net loss · Q3-2025 | $-2M | |
| Research and Development expenses · Q3-2025 | $1M | |
| General and Administrative expenses · Q3-2025 | $900000.00 |
Risks flagged
Cash runway only through Q4 2026; need for additional financing to launch Phase 3
“Cash runway expected through end of Fourth Quarter of 2026; Phase 3 trial launch subject to financial resources” · word for word
Chemomab Therapeutics Ltd. — questions
- What did Chemomab Therapeutics Ltd. file recently?
- 16 SEC filings in the last 12 months. Latest: 6-K on 2026-10-19 — Amendment to merger agreement for redomiciliation and merger with Scipher Medicine; reduces combined company shares to 5M; CVR agreement amended.
Every figure on this page comes from Chemomab Therapeutics Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.